Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.42 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14996245 | 0.88 | TSHR (0.44) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL14996240 | 0.86 | TSHR (0.43) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL21016081 | 0.85 | FAAH (0.45) | SMN1; SMN2HTTKMT2AMEN1HPGD | |
| SCHEMBL24935539 | 0.82 | TSHR (0.51) | KMT2AMEN1HPGDLMNAPKM | |
| SCHEMBL2730627 | 0.82 | SPR (0.49) | HTTKMT2AMEN1HPGDLMNA | |
| SCHEMBL13328238 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL12384295 | 0.80 | TSHR (0.53) | SMN1; SMN2HTTKMT2AMEN1GAA | |
| SCHEMBL23471188 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL2976450 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL20939040 | 0.79 | KMT2A (0.46) | SMN1; SMN2HTTKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350181-B1 | HER3 LIGANDS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-20210230183-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-29 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | SMN1; SMN2 4182/4885HTT 2073/4885KMT2A 1949/4885 |
| US-20210230183-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | SMN1; SMN2 3432/4885HTT 2363/4885KMT2A 1832/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | SMN1; SMN2 4182/4885HTT 2073/4885KMT2A 1949/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | SMN1; SMN2 4086/4885HTT 2128/4885KMT2A 1997/4885 |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SMN1; SMN2 3489/4885HTT 854/4885KMT2A 3370/4885 |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SMN1; SMN2 3489/4885HTT 854/4885KMT2A 3370/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SMN1; SMN2 3489/4885HTT 854/4885KMT2A 3370/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | SMN1; SMN2 3143/4885HTT 1802/4885KMT2A 1262/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SMN1; SMN2 3489/4885HTT 854/4885KMT2A 3370/4885 |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | SMN1; SMN2 3489/4885HTT 854/4885KMT2A 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.